Richard Hausmann Appointed as CEO of Combinostics

Tampere, Finland, Wednesday 19, 2021—Combinostics, provider of artificial intelligence (AI) technology to help clinicians make evidence-based decisions for the diagnosis and management of neurological disorders, today announced that Richard Hausmann has been named as Chief Executive Officer, effective June 1, 2021. Hausmann will succeed Lennart Thurfjell, who is one of the founders of Combinostics and current Chief Executive Officer. Thurfjell will transition to the role of Chief Operating Officer.
“Richard brings decades of leadership and healthcare experience to Combinostics,” said Thurfjell. “His expertise and ability to bring innovative solutions to the global healthcare market will further drive our mission of supporting clinicians in providing the best care for their patients with neurological disorders.”
Hausmann has been a leader at publicly traded companies for more than 30 years and holds a PhD in Physics. Most recently, he served as President and CEO of Elekta AB, a Swedish-based cancer care company. He also served as President and CEO of GE Healthcare’s Magnetic Resonance (MR) division and spent two decades in various leadership positions in the Medical Engineering division of Siemens AG. Additionally, Hausmann served as the President and CEO of Siemens Limited China.
“I look forward to joining the strong team at Combinostics,” said Hausmann. “The company’s combination of expertise in both science and technology puts us in a unique position to support physicians in providing patients with an objective diagnosis as early as possible, which can improve the quality of life for patients and their caregivers. I am excited to be a part of this journey.”

About Combinostics

The Combinostics cNeuro™ platform combines the company’s innovative AI technology with a holistic view of patient data (imaging biomarkers, demographic and clinical data, neuropsychology test results, and other biomarkers) to enable clinicians to make reliable, evidence-based diagnostic and management decisions for their patients with neurological disorders.

Recent News & Events

cNeuro 2.0

Combinostics today announced the release of cNeuro® cMRI 2.0 and cneuro® cDSI 2.0. The main benefit of the new release is modularization of the system,

Read More »